Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2

Kasey Price1, William H Yang1, Leticia Cardoso1

  • 1Department of Biomedical Sciences, School of Medicine, Mercer University, Savannah, GA 31404, USA.

Cancers
|March 13, 2024
PubMed

Insights

Jun dimerization protein 2 (JDP2) directly interacts with and enhances p53 transactivation by reducing MDM2 levels. This study reveals JDP2 as a novel regulator of the p53 and MDM2 proteins.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Protein-Protein Interactions

Background:

  • The Activator Protein-1 (AP-1) complex includes proteins like Jun dimerization protein 2 (JDP2).
  • JDP2 plays roles in cell-cycle regulation, cancer, and immunity.
  • Previous research explored ATF3's influence on p53, but JDP2's direct interaction with p53 was unknown.

Purpose of the Study:

  • To investigate the direct interaction between JDP2 and p53.
  • To determine JDP2's regulatory role in p53 transactivation.
  • To elucidate the mechanism by which JDP2 affects p53 activity.

Main Methods:

  • Co-immunoprecipitation assays to confirm JDP2-p53 interaction.
  • Reporter gene assays (p53 (14X)RE-Luc) to measure p53 transactivation.
  • CHX chase experiments to assess p53 protein stability.
  • Western blotting to analyze protein levels, including MDM2.

Main Results:

  • JDP2 directly binds to p53, with the C-terminal domain of JDP2 being critical for this interaction.
  • JDP2 significantly enhances p53 transactivation in p53-null cells and additively with ATF3.
  • JDP2 increases p53 stability and reverses MDM2-induced p53 repression, likely by reducing MDM2 levels.

Conclusions:

  • JDP2 directly interacts with p53 and enhances its transactivation.
  • JDP2 functions as a novel regulator of p53 and MDM2.
  • These findings suggest JDP2 as a potential target in cancer therapies involving p53 regulation.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K